Ac-LKKTETQ comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-03-20. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Calculated for the acetylated heptapeptide |
| Molecular weight | ~889 Da | Monoisotopic mass approximately 889.0 Da |
| Amino acid sequence | Ac-LKKTETQ | N-terminal acetylated seven-residue peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilized solid |
| Solubility class | Water-soluble | Peptides of this size generally dissolve in aqueous media |
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
== History == Alec D. Bangham discovered liposomes in the 1960s as spherical vesicles made of a phospholipid bilayer that houses hydrophilic cores. The liposomes were then studied to uncover the properties of biological membranes and a hydration method was discovered to prepare artificial liposomes from 1968 to 1975. Since then, multiple methods of preparing liposomes have been utilized and their characteristics (physical and chemical) have been studied. Monoclonal antibodies are proteins that stick to specific antigens that tag specific cells and can be synthesized in the lab. They were first generated in 1975 and have since advanced to being used for immunotherapy. Immunolipsomes were developed utilizing both of these components. The first anticancer drug made with this method was doxorubicin (DOX) in the 1990s.
Capillary electrophoresis–mass spectrometry (CE–MS) is an analytical chemistry technique formed by the combination of the liquid separation process of capillary electrophoresis with mass spectrometry. CE–MS combines advantages of both CE and MS to provide high separation efficiency and molecular mass information in a single analysis. It has high resolving power and sensitivity, requires minimal volume (several nanoliters) and can analyze at high speed. Ions are typically formed by electrospray ionization, but they can also be formed by matrix-assisted laser desorption/ionization or other ionization techniques. It has applications in basic research in proteomics and quantitative analysis of biomolecules as well as in clinical medicine. Since its introduction in 1987, new developments and applications have made CE-MS a powerful separation and identification technique. Use of CE–MS has increased for protein and peptides analysis and other biomolecules. However, the development of online CE–MS is not without challenges. Understanding of CE, the interface setup, ionization technique and mass detection system is important to tackle problems while coupling capillary electrophoresis to mass spectrometry.
By the early 1940s, Rausing (now the sole owner of the company) began developing dairy packaging that could compete with loose milk. Erik Wallenberg, an assistant in the Åkerlund & Rausing lab, came up with the idea to construct a tetrahedron-shaped package out of a tube of paper in 1944. On 27 March 1944, Rausing filed a patent for the idea. Rausing's wife Elisabeth reportedly came up with the idea of continuously sealing the packages through the milk while filling the tube in the manner of stuffing sausages. In 1946, the company introduced the first prototype tetrahedron-package filling machine.
== Operation Atlantic Resolve == On 29 March 2017, the Department of Defense reported that Green Berets from 1st Battalion 10th SFG were deployed to Europe to take part in exercise Allied Spirit VI-a multinational training exercise involving military personnel from Canada, Czech Republic, Estonia, Finland, France, Hungary, Germany, Italy, Macedonia, Kosovo, Latvia, the Netherlands, Slovenia, UK and US at the JMRC in Germany, the exercise involved special operations and conventional forces with the aim to increase their effectiveness and/particularly to increase the effectiveness of special operations forces in working together while bolstering the capabilities of partner nations within US European Command's area of responsibility. The Green Berets provided their advise and assist training/skills, whilst working with Estonian Special Operations Task Group troops and Macedonian special operations troops. US Army Major Robert Temple, the special operations force cell planner at the JMRC said that “The primary purpose of this exercise is providing a venue for the 1st Latvian Brigade to train in a Joint Task Force environment and increase their interoperability with both U.S. units as well as other multinational forces.” The exercise is being conducted as part of Operation Atlantic Resolve.
Sources: en.wikipedia.org
In the New Testament, the Epistle to the Colossians sets out a partial list: "everything visible and everything invisible, Thrones, Dominions, Sovereignties, Powers – all things were created through him and for him." The Epistle to the Ephesians also lists several entities: "Far above all principality, and power, and might, and dominion, and every name that is named, not only in this world, but also in that which is to come". In the 5th and 6th centuries, Pseudo-Dionysius the Areopagite set out a more elaborate hierarchy, consisting of three lists, each of three types:
Common impurities include metals like copper and lead; chemical compounds such as pesticides, PFAS, or bleach; and harmful bacteria, such as Campylobacter, E. coli O157, and Vibrio. Some solutes are acceptable and even desirable for taste enhancement and to provide needed electrolytes. The single largest (by volume) freshwater resource suitable for drinking is Lake Baikal in Siberia.
being aged 45 or older having African American, Alaska Native, American Indian, Asian American, Hispanic/Latino, Native Hawaiian, or Pacific Islander American ethnicity having health conditions such as high blood pressure and abnormal cholesterol levels having a history of gestational diabetes having a history of heart disease or stroke. In addition, some medications and other health conditions can raise the risk.
Sources: en.wikipedia.org
The mechanism of action of the P7C3 series of compounds involves activation of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme responsible for the transformation of nicotinamide into nicotinamide adenine dinucleotide (NAD). By activating NAMPT, the P7C3 compounds result in an increase in intracellular levels of NAD.
There has yet to be any academic evidence for the idea that there were significant forces considered loyal to the old regime. Rather, the continued fighting which was seen after the flight of Ceaușescu is believed to have been a result of mistaken exchanges of fire from the general population and armed forces. There has been no academic evidence to suggest that Securitate units fought against the revolution. The origins of this story can be found in the speech given on 22 December by Army Captain Mihail Lupoi. During this speech, he asserts that it was only the Securitate who had shot protesters before the 22nd and that the Securitate needs to come onto the side of the army. This placed the deaths of protesters by the army onto the shoulders of the Securitate. But both the army and Securitate had shot and killed protesters before the 22nd. The vast majority of deaths came from the period between 22 and 25 December. On the 22nd, a small group of individuals which would later comprise the core of the National Salvation Front (Romanian: Frontul Salvării Naționale, FSN), called for a mass mobilisation of people for the defence of the television station. This call to arms resulted in the accumulation of army personnel, patriotic guards (both in and out of uniform) and armed civilians guarding the station. Later the same evening, there was an announcement that a convoy of anti-terrorist units were heading for the television centre. This was not so, but it added to the extremely tense environment which had been building since the flight of Ceaușescu.
On January 26, 2006, Chipotle made its initial public offering (IPO) after increasing the share price twice due to high pre-IPO demand. At the time, Chipotle had 500 stores. In its first day as a public company, the stock rose exactly 100%, resulting in the best U.S.-based IPO in six years, and the second-best IPO for a restaurant after Boston Market. The money from the offering was then used to fund new store growth. In March 2005, Monty Moran was appointed president and chief operating officer of Chipotle while Ells remained chairman and CEO. In October 2006, McDonald's fully divested from Chipotle. This was part of a larger initiative for McDonald's to divest all of its non-core business restaurants—Chipotle, Donatos Pizza, and Boston Market—so that it could focus on the main McDonald's chain. McDonald's had invested approximately $360 million into Chipotle, and took out $1.5 billion. McDonald's had attempted to get Chipotle to add drive-through windows and a breakfast menu, which Ells resisted. In 2008, Chipotle opened its first location outside of the United States in Toronto. In January 2009, president and chief operating officer Monty Moran was promoted to co-CEO, a position that he would share with Ells, while Moran retained his president position. In a list of fastest-growing restaurant chains in 2009, Chipotle was ranked eighth, based on increases in U.S. sales over the past year, and in 2010 Chipotle was ranked third. Consumer Reports ranked Chipotle as the best Mexican fast-food chain in 2011. The company serves approximately 750,000 customers per day.
== Early life and education == Ly was born in Cambodia and survived the Cambodian genocide. He emigrated to the United States as a refugee in 1984. Ly earned a bachelor's degree in chemical engineering from the Georgia Institute of Technology. He subsequently received a Ph.D. in bioorganic chemistry from the same institution. He completed postdoctoral research at the University of California, Berkeley and The Scripps Research Institute under Peter G. Schultz, where his research included studying cellular alterations related to aging.
Sources: en.wikipedia.org
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.
No. Thymosin beta-4 is a 43-amino-acid protein, while TB-500 represents only a short N-terminal segment. The two should not be treated as interchangeable in experimental design.
It is often called a thymosin beta-4 fragment, Tβ4 fragment, or Ac-LKKTETQ. The name TB-500 is mainly a commercial or catalog label rather than a formal chemical name.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.